Remnant Cholesterol Markers Flag Kidney Disease Risk
Two posters at ASN Kidney Week 2026 point to remnant cholesterol as a possible tool for assessing cardiovascular and kidney disease risk.
Updated on Nov. 3, 2026 in Heart Disease
Researchers presenting at ASN Kidney Week 2026 in Denver reported that remnant cholesterol, calculated from a standard lipid panel, may help stratify risk in patients with chronic kidney disease. In a study of 346 hemodialysis patients, those with higher remnant cholesterol had a 35.8% cardiovascular disease mortality rate versus 1.16% in the lower group.
Why it matters
Cardiovascular disease is a leading cause of death among people with kidney disease, and existing risk tools may not fully capture it. If remnant cholesterol proves a reliable marker, it could be measured with routine lipid testing rather than specialized equipment.
The hemodialysis study enrolled 346 patients from 2010 to 2025, with 64 of 118 deaths attributed to cardiovascular disease, and high remnant cholesterol was an independent risk factor for cardiovascular mortality (HR, 26.642; P < .001). In the CKD study of 1644 patients, CTI showed an odds ratio of 2.17 for advanced CKD risk, while CRP was not significantly associated with risk stratification (P = .379).
The players
American Society of Nephrology (ASN)
The American Society of Nephrology is a professional organization of kidney specialists that hosts the annual Kidney Week conference, where the research was presented.
Peking University Third Hospital
Peking University Third Hospital is a major teaching hospital in Beijing, China, whose researchers conducted the hemodialysis study cited in the posters.
The details
Remnant cholesterol is calculated as total cholesterol minus LDL cholesterol minus HDL cholesterol. In the hemodialysis study, patients were split at a median value of 0.72 mmol/L, and the higher group showed markedly greater cardiovascular deaths. A separate retrospective analysis of 1644 CKD patients treated between 2011 and 2020 found that remnant cholesterol-based indices outperformed CRP in assessing disease risk.
Timeline
2010 to 2025: Enrollment period for the hemodialysis study of 346 patients.
2011 to 2020: Treatment period for the 1644 CKD patients in the retrospective study.
October 24, 2026: Poster presentations at ASN Kidney Week 2026 in Denver.
Health Landscape
For decades, cardiovascular risk guidance has centered on LDL cholesterol as the primary lipid target. These posters suggest that remnant cholesterol, which is largely carried in triglyceride-rich lipoproteins, may capture cardiovascular risk in kidney disease patients that LDL alone misses.
Because remnant cholesterol can be derived from a standard lipid panel, patients on dialysis or with chronic kidney disease may eventually have it considered in routine cardiovascular assessment. Anyone with kidney disease should keep discussing lipid results and heart risk with their own care team.
The takeaway
Remnant cholesterol may offer a practical, low-cost addition to cardiovascular risk assessment for people with kidney disease. Larger prospective studies will be needed before it changes clinical practice.
Further reading
For related context on cardiovascular risk factors, see our Heart Disease coverage.
Source note: This article includes information reported by Pharmacytimes.
